CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DKRASExon 2 MutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerVemurafenibYang et al., 2012
DBCL2F104IPredictiveSupportsResistanceFollicular LymphomaVenetoclaxBlombery et al., 2019
CVHLR167W (c.499C>T)PredisposingN/AVon Hippel-Lindau DiseasePozo et al., 2005
CVHLL184P (c.551T>C)PredisposingN/AVon Hippel-Lindau DiseaseWong et al., 2008
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,Irinotecan,CetuximabYang et al., 2012
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,ErlotinibYang et al., 2012
CBCR::ABL1Fusion AND ABL1 Y253FPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
BPIK3CAMutationPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
AZFTA::RELAFusionDiagnosticSupportsPositiveSupratentorial Ependymoma, ZFTA Fusion–positiveLouis et al., 2016
DFGFR3S249CPredictiveSupportsResistanceTransitional Cell CarcinomaCisplatinXie et al., 2019
DFLT3Y842CPredictiveSupportsResistanceAcute Myeloid LeukemiaQuizartinibWilliams et al., 2013
BPIK3CAMutationPredictiveSupportsResistanceHer2-receptor Positive Breast CancerCapecitabine,LapatinibBaselga et al., 2016
BPTENLossPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
CVHLP86S (c.256C>T)PredisposingN/AVon Hippel-Lindau DiseaseCorcos et al., 2008
BKRASMutationPredictiveSupportsSensitivity/ResponseOvary Serous AdenocarcinomaBinimetinibMonk et al., 2020
DBCL2G101VPredictiveSupportsResistanceChronic Lymphocytic LeukemiaVenetoclaxBirkinshaw et al., 2019
DFGFR3S249CFunctionalSupportsGain of FunctionDel Piccolo et al., 2015
DFGFR3S249COncogenicSupportsOncogenicityTransitional Cell Carcinomadi Martino et al., 2009
CIDH1MutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaVenetoclaxHuemer et al., 2019
CIDH2MutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaVenetoclaxHuemer et al., 2019
DFLT3N841IPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaMidostaurinJiang et al., 2004
CSQSTM1::NTRK1FusionPredictiveSupportsSensitivity/ResponseCongenital FibrosarcomaLarotrectinibDuBois et al., 2018
BATRXMutationDiagnosticSupportsPositiveMalignant AstrocytomaKannan et al., 2012
CLMNA::NTRK1FusionPredictiveSupportsSensitivity/ResponseCongenital FibrosarcomaCrizotinibBender et al., 2019
DFGFR3Y373COncogenicSupportsOncogenicityUrinary Bladder CancerBernard-Pierrot et al., 2006
BPAX3::FOXO1FusionPrognosticSupportsPoor OutcomeAlveolar RhabdomyosarcomaSorensen et al., 2002
BPAX7::FOXO1FusionPrognosticSupportsBetter OutcomeAlveolar RhabdomyosarcomaSorensen et al., 2002
CLMNA::NTRK1FusionPredictiveSupportsSensitivity/ResponseSpindle Cell SarcomaTRK InhibitorSo et al., 2020
DLMNA::NTRK1FusionOncogenicSupportsOncogenicitySpitzoid MelanomaWiesner et al., 2014
CLMNA::NTRK1FusionDiagnosticSupportsPositiveSpitzoid MelanomaWiesner et al., 2014
DFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
DETV6::NTRK3FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaLarotrectinibSchewe et al., 2019
DKIAA1549::BRAFFusionPredictiveSupportsSensitivity/ResponseChildhood Pilocytic AstrocytomaTrametinibSelt et al., 2017
BTP53OverexpressionPrognosticSupportsPoor OutcomeRenal Wilms' TumorJadali et al., 2011
CVHLR167W (c.499C>T)PredisposingN/AVon Hippel-Lindau DiseaseHuddle, 2011
CVHLF76del (c.227_229del)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLN78S (c.233A>G)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLP81S (c.241C>T)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLP86S (c.256C>T)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLP86L (c.257C>T)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLW88S (c.263G>C)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLT157I (c.470C>T)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLC162R (c.484T>C)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLC162Y (c.485G>A)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLR167W (c.499C>T)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLR167Q (c.500G>A)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLL178P (c.533T>C)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLNull (Large deletion)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLR120fs (c.358_359insAC)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
CVHLS80fs (c.239del)PredisposingSupportsPredispositionVon Hippel-Lindau Disease1995
Page 58 of 96
PreviousNext